Zheng Quan Shi Bao Wang·2026-01-23 00:53Core Viewpoint - Bangshun Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the exclusive sponsor. The company focuses on oncology and autoimmune diseases, with a pipeline that includes one NDA-stage product, one registration clinical-stage product, and five preclinical candidates [1]. Company Summary - The core product, Bezeqitinib, is a JAK inhibitor expected to be among the first domestically approved treatments for myelofibrosis (MF) in China, with an NDA submitted and approval anticipated in Q2 2026. It is also a leading JAK inhibitor for treating polycythemia vera (PV) in China and essential thrombocythemia (ET) globally [1]. - Another key product, CX1440, is a BTK inhibitor currently in Phase III clinical trials, ranking among the top three globally for treating immune thrombocytopenia (ITP) and among the top two for chronic urticaria (CU) and autoimmune hemolytic anemia (AIHA) [1]. Industry Summary - The Chinese myeloproliferative neoplasm (MPN) market is projected to grow from $900 million in 2024 to $1.6 billion by 2030. The market for autoimmune disease drugs in China is expected to increase from $4.6 billion in 2024 to $18.4 billion by 2030 [1].